Vaxart Competitors, Revenue, Alternatives and Pricing

Claim your profile

Overview

Location:
Total Funding:$58.6M
Industry:Biotech
Founded:2004
Lead Investor(s):Care Capital

Industry Ranking

Estimated Revenue & Financials

  • Vaxart's estimated annual revenue is currently $4.2M per year.
  • Vaxart received $18.4M in venture funding in January 2015.
  • Vaxart's estimated revenue per employee is $122,324
  • Vaxart's total funding is $58.6M.

Employee Data

  • Vaxart has 34 Employees.
  • Vaxart grew their employee count by -17% last year.
  • Vaxart currently has 1 job openings.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingOnline ReviewPricing
#1
$7M4510%N/A-N/A
#2
N/A205N/AN/A-N/A
#3
$46.8M3024%N/A-N/A
#4
$22.3M144N/AN/A-N/A
#5
$44.3M286N/AN/A-N/A
#6
$101.2M65346%N/A-N/A
#7
$18.6M120N/AN/A-N/A
#8
$23.3M150N/AN/A-N/A
#9
$33.3M2153%N/A-N/A
#10
$28.7M1858%N/A-N/A
Missing a competitor? Contribute!?
Submit

Vaxart is a clinical-stage company developing tablet vaccines based on its proprietary oral vaccine platform. The lead programs are prophylactic oral vaccines for seasonal influenza, RSV and norovirus, as well as a therapeutic vaccine for HPV types 16 and 18. Vaxart vaccines are convenient room temperature-stable tablets that are easy to administer, and that eliminate risk of needle-stick injury and medical waste associated with injectable vaccines. The company is listed on the NASDAQ exchange under ticker nymbol VXRT.

keywords:Biotechnology,Healthcare,Pharmaceuticals

34

Number of Employees

$4.2M

Revenue (est)

1

Current Jobs

-17%

Employee Growth %

$58.6M

Total Funding

N/A

Valuation

N/A

Accelerator

B2B

Type

Vaxart News

09/07/2019 - Vaxart to Present at the HC Wainwright 21st Annual Global ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--. Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant ...

09/08/2019 - Vaxart (NASDAQ:VXRT) Now Covered by Analysts at ...

Stock analysts at Brookline Capital Management assumed coverage on shares of Vaxart (NASDAQ:VXRT) in a research note issued on ...

09/07/2019 - Vaxart (NASDAQ:VXRT) Given a $2.00 Price Target at HC ...

Vaxart (NASDAQ:VXRT) has been given a $2.00 target price by HC Wainwright in a research note issued on Wednesday, August 21st, ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal FundingOnline ReviewPricing
#1
$5.3M3455%N/A-N/A
#2
$7.2M35N/AN/A-N/A
#3
$5.4M3552%N/A-N/A
#4
$6.2M4054%N/A-N/A
#5
$6.2M4082%N/A-N/A

Vaxart Funding

DateAmountRoundLead InvestorsReference
2007-11-16$3.3MAQuantum Technology Partners, Life Science AngelsArticle
2010-03-05$12.5MBCare Capital of Princeton NJArticle
2013-08-07$20.0MCArticle
2015-01-09$18.4MUndisclosedCare CapitalArticle

Vaxart Executive Hires

DateNameTitleReference
2014-05-09John M. HarlandCFOArticle
2016-02-10Samir SinghSVP corporate development and strategy.Article
2018-04-20Brant BiehnSVP Commercial OperationsArticle
2018-05-02David TaylorChief Medical OfficerArticle

Vaxart Acquisitions

DateCompany NameAmountNotesReference
2018-02-01Aviragen TherapeuticsArticle
2018-02-14Aviragen TherapeuticsArticle